Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Triple-Negative Breast Cancer -

Triple-Negative Breast Cancer

Biomarkers, Emerging Therapeutic Strategies & Clinical Challenges

Marion Montgomery (Herausgeber)

Buch | Softcover
94 Seiten
2017
Nova Science Publishers Inc (Verlag)
978-1-5361-2372-2 (ISBN)
CHF 169,95 inkl. MwSt
  • Versand in 15-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Poorly differentiated triple negative breast cancers (TNBCs) were first characterized in the literature in 2005 by the absence of receptors for estrogen (ER) and progesterone (PR) as well as the lack of tyrosine kinase human epidermal growth factor receptor 2 (HER-2). Clinically, TNBCs exhibit fairly aggressive local growth, rapid progression and account for a high rate of early metastases, most commonly to visceral organs and central nervous system. Chapter One describes how the last decade has contributed to our understanding of the function of exosomes in the progression of breast cancer. Furthermore, it will discuss the implications for using exosomes from body fluids as biomarkers in diagnosis and treatment strategies. Chapter Two discusses how the strong correlation between BRCA gene mutations and the high risk of TNBC proposes certain mediators between germline mutations and the risk for poorly differentiated breast cancers. Chapter Three presents increasing evidence of the role of tumor lymphocytic immune infiltrates in this subtype of breast cancer. High levels of tumor infiltrating lymphocytes (TILs), mainly in lymphocyte-predominant breast cancer (LPBC), have been associated with improved disease-free and overall survival rates in TNBC patients with and without any treatment.

Preface; The Role of Exosomes in Breast Cancer: What Have We Learned in Ten Years?; Correlations between BRCA Gene Mutations & the High Risk of TNBC as Defined by the Defect of Estrogen Signaling; The Role of Tumor Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancer (TNBC); Index.

Erscheinungsdatum
Verlagsort New York
Sprache englisch
Maße 155 x 230 mm
Gewicht 206 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
ISBN-10 1-5361-2372-2 / 1536123722
ISBN-13 978-1-5361-2372-2 / 9781536123722
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
CHF 37,80
Resilienz innovativ stärken : ein Praxishandbuch

von Christa Diegelmann; Margarete Isermann; Tanja Zimmermann

Buch | Softcover (2023)
Kohlhammer (Verlag)
CHF 49,95